ResultsIQ

ResultsIQ › Latest results › Sai Life Sciences Limited

Sai Life Sciences Limited Q4 FY25 results deck summary

NSE: SAILIFE · BSE: 544306

Results deck of 14 May 2025, summarised by AI from the filing.

Management expects lower interest costs starting FY26 after completing the planned ₹720 cr debt repayment.

Key takeaways

  1. Interest costs Management expects lower interest costs starting FY26 after completing the planned ₹720 cr debt repayment.
  2. Peptide centre Peptide Research Centre launched to meet growing demand for complex peptide synthesis and conjugation.
  3. Forward-looking risk Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.

Original filing on BSE

Sai Life Sciences Limited Q1 FY27 results

As filed: Revenue ₹554 cr (+12% year on year), EBITDA ₹148 cr (+22% year on year), PAT ₹73.3 cr (+22% year on year), EBITDA margin 26.7% (+231 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹602 cr (+4% year on year), EBITDA ₹177 cr (+12% year on year), PAT ₹104 cr (+18% year on year), EBITDA margin 29.3% (+225 bps). Score 53 of 100, In line with trend. EBITDA margin rose 225 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.5% in 30 days (Nifty 500: −3.8%).
  • Q3 FY26: Revenue ₹556 cr (+26% year on year), EBITDA ₹188 cr (+57% year on year), PAT ₹100 cr (+86% year on year), EBITDA margin 33.8% (+649 bps). Score 92 of 100, Above trend. EBITDA margin rose 649 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +21.7% in 30 days (Nifty 500: +1.5%).
  • Q2 FY26: Revenue ₹527 cr, EBITDA ₹140 cr, PAT ₹83.0 cr, EBITDA margin 26.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.0% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹483 cr, EBITDA ₹113 cr, PAT ₹58.0 cr, EBITDA margin 23.4%. Not scored. No result for the same quarter last year. Share price after the results: +8.7% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹567 cr, EBITDA ₹153 cr, PAT ₹90.0 cr, EBITDA margin 27.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.1% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹429 cr, EBITDA ₹112 cr, PAT ₹51.0 cr, EBITDA margin 26.1%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Sai Life Sciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.